Michael Hayden, a former executive of Teva Pharmaceuticals Industries Ltd, has joined the board of Oxford Biomedica Plc as a non-executive director to help guide the company’s cell and gene therapy business. Dr Hayden was president of global R&D and chief scientific officer at Teva during which time the company secured regulatory approval for about 35 products. He has also been the co-founder of five biotech companies including Prilenia Therapeutics BV where he is currently CEO. Prilenia’s lead asset is for Huntington’s disease.
Oxford Biomedica announced the appointment on 15 July 2021.
Copyright 2021 Evernow Publishing Ltd